

Allentown, Pennsylvania 18106, made application to the Drug Enforcement Administration (DEA) for registration as an importer of Tapentadol (9780), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance to conduct clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than December 10, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012–27437 Filed 11–8–12; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer Of Controlled Substances; Notice of Registration; Boehringer Ingelheim Chemicals, Inc.**

By Notice dated July 17, 2012, and published in the **Federal Register** on

July 26, 2012, 77 FR 43861, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance to bulk manufacture amphetamine.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Boehringer Ingelheim Chemicals, Inc., to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971.

DEA has investigated Boehringer Ingelheim, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012–27440 Filed 11–8–12; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application; Noramco, Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 9, 2012, Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                                     | Schedule |
|--|----------|
| Gamma Hydroxybutyric Acid (2010).        | I        |
| Codeine-N-oxide (9053) .....             | I        |
| Dihydromorphine (9145) .....             | I        |
| Morphine-N-oxide (9307) .....            | I        |
| Amphetamine (1100) .....                 | II       |
| Methylphenidate (1724) .....             | II       |
| Codeine (9050) II Dihydrocodeine (9120). | II       |
| Oxycodone (9143) .....                   | II       |
| Hydromorphone (9150) .....               | II       |
| Hydrocodone (9193) .....                 | II       |
| Morphine (9300) .....                    | II       |
| Oripavine (9330) .....                   | II       |
| Thebaine (9333) .....                    | II       |
| Oxymorphone (9652) .....                 | II       |
| Noroxymorphone (9668) .....              | II       |
| Alfentanil (9737) .....                  | II       |
| Sufentanil (9740) .....                  | II       |
| Carfentanil (9743) .....                 | II       |
| Tapentadol (9780) .....                  | II       |
| Fentanyl (9801) .....                    | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 8, 2013.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012–27394 Filed 11–8–12; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey, Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 10, 2012, Johnson Matthey, Inc., Pharmaceuticals Materials, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                             | Schedule |
|----------------------------------|----------|
| Gamma Hydroxybutyric Acid (2010) | I        |
| Amphetamine (1100)               | II       |
| Methylphenidate (1724)           | II       |
| Codeine (9050)                   | II       |
| Oxycodone (9143)                 | II       |

  

| Drug                          | Schedule |
|-------------------------------|----------|
| Diphenoxylate (9170)          | II       |
| Hydrocodone (9193)            | II       |
| Meperidine (9230)             | II       |
| Methadone (9250)              | II       |
| Methadone intermediate (9254) | II       |
| Morphine (9300)               | II       |
| Thebaine (9333)               | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

The Thebaine (9333) will also be used to manufacture other controlled substances for sale in bulk to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register Representative (ODL)**, 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 8, 2013.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-27398 Filed 11-8-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application, Cody Laboratories, Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 30, 2012, Cody Laboratories, Inc., ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug   | Schedule |
|--|----------|
| Dihydromorphine (9145)                           | I        |
| Amphetamine (1100)                               | II       |
| Methamphetamine (1105)                           | II       |
| Amobarbital (2125)                               | II       |
| Pentobarbital (2270)                             | II       |
| Secobarbital (2315)                              | II       |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333) | II       |
| Phenylacetone (8501)                             | II       |
| Cocaine (9041)                                   | II       |
| Codeine (9050)                                   | II       |
| Dihydrocodeine (9120)                            | II       |
| Oxycodone (9143)                                 | II       |
| Hydromorphone (9150)                             | II       |
| Diphenoxylate (9170)                             | II       |
| Ecgonine (9180)                                  | II       |
| Hydrocodone (9193)                               | II       |
| Meperidine (9230)                                | II       |
| Methadone (9250)                                 | II       |
| Morphine (9300)                                  | II       |
| Thebaine (9333)                                  | II       |
| Oxymorphone (9652)                               | II       |
| Alfentanil (9737)                                | II       |
| Remifentanil (9739)                              | II       |
| Sufentanil (9740)                                | II       |
| Fentanyl (9801)                                  | II       |

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register Representative (ODL)**, 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 8, 2013.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-27401 Filed 11-8-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances Notice of Application; National Center For Natural Products Research (NIDA MPROJECT)**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 17, 2012, National Center for Natural Products Research—NIDA MProject, University of Mississippi, 135 Coy Waller Complex, University, Mississippi 38677, made application by renewal to the Drug

Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug                         | Schedule |
|------------------------------|----------|
| Marihuana (7360)             | I        |
| Tetrahydrocannabinols (7370) | I        |

The company plans to cultivate marihuana for the National Institute on Drug Abuse for research approved by the Department of Health and Human Services.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register Representative (ODL)**, 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 8, 2013.

Dated: November 1, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-27441 Filed 11-8-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application; INB Hauser Pharmaceutical Services, Inc.**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 20, 2012, InB Hauser Pharmaceutical Services, Inc., 6880 N. Broadway, Suite H, Denver, Colorado 80221, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 4-Anilino-N-phenethyl-4-piperidine (8333), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance in bulk for distribution and sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in